Last updated: November 3, 2026
Sucraid is a niche enzyme-replacement product used to treat congenital sucrase-isomaltase deficiency, or CSID. QOL Medical owns and commercializes the product in the United States. Its market has high revenue concentration, limited direct competition, substantial diagnosis constraints, and no publicly reported product-level sales. The original seven-year orphan-drug exclusivity period expired in 2008, but Sucraid has retained commercial protection through specialized manufacturing, physician familiarity, reimbursement infrastructure, and the small diagnosed patient population.
What is Sucraid and how does it work?
Sucraid is an oral solution containing sacrosidase, a recombinant form of the sucrase enzyme produced in Saccharomyces cerevisiae. It replaces deficient intestinal sucrase activity and helps patients digest sucrose and certain starch-derived sugars.
| Product attribute |
Sucraid detail |
| Active ingredient |
Sacrosidase |
| Dosage form |
Oral solution |
| Strength |
8,500 International Units per mL |
| FDA indication |
Treatment of sucrase deficiency in patients with CSID |
| FDA approval |
2001 |
| Current commercial company |
QOL Medical, LLC |
| Administration |
Taken with meals and snacks |
| Storage |
Refrigerated at 2°C to 8°C |
| Primary market |
United States rare-disease and specialty-pharmacy market |
The labeled dose is generally 1 mL with each meal or snack for patients weighing 15 kilograms or less and 2 mL for patients above 15 kilograms. The product must be mixed with water or milk and should not be added to hot liquids because heat can reduce enzyme activity. [1]
Sucraid addresses the underlying digestive enzyme deficiency but does not eliminate the need for dietary management. Treatment is therefore linked to every meal and snack, producing recurring demand among diagnosed and treated patients.
How large is the Sucraid market?
The addressable market is limited by three factors: the rarity of clinically recognized CSID, underdiagnosis, and the need for confirmatory testing or specialist evaluation.
CSID is associated with mutations or functional abnormalities affecting the sucrase-isomaltase enzyme complex. Symptoms can overlap with irritable bowel syndrome, functional diarrhea, inflammatory bowel disease, lactose intolerance, and other gastrointestinal disorders. This overlap delays diagnosis and restricts the treated population.
The commercial market has several favorable characteristics:
- Treatment is chronic rather than episodic.
- Dosing occurs with meals and snacks.
- There is no widely established therapeutic substitute that directly replaces sacrosidase.
- Patients often rely on specialty physicians and specialty pharmacies.
- Product demand can expand if gastroenterologists improve recognition of CSID.
The principal market constraint is not necessarily biological prevalence. It is the number of patients who receive a diagnosis, obtain coverage, and remain on treatment.
What is the estimated patient opportunity?
Public sources do not provide a verified, current Sucraid patient count or audited market-size figure. QOL Medical is privately held and does not publish Sucraid revenue, prescription volume, net price, or treated-patient data.
A practical commercial model is therefore based on diagnosed prevalence rather than total potential prevalence:
| Market stage |
Commercial effect |
| Symptomatic population |
Large but nonspecific |
| Patients evaluated by gastroenterologists |
Smaller |
| Patients tested or clinically diagnosed with CSID |
Smaller still |
| Patients approved by insurers |
Restricted further |
| Persistently treated patients |
Core recurring revenue base |
This structure creates a high-value, low-volume specialty market. Revenue can grow without broad population penetration if diagnosis and payer approval improve.
What is Sucraid’s financial trajectory?
Sucraid’s financial trajectory cannot be quantified from public company filings because QOL Medical does not disclose product-level sales or earnings. No reliable public source establishes annual Sucraid revenue, gross margin, operating profit, or prescription count.
The product’s likely financial profile is defined by four characteristics:
- Recurring treatment demand.
- High revenue concentration in a single branded product.
- Specialty distribution and reimbursement support.
- Limited volume growth unless diagnosis expands.
The product likely generates a more stable revenue stream than an acute-use medicine because patients use it repeatedly with meals. However, the small patient population limits absolute revenue scale. Commercial growth is more likely to come from patient identification, payer access, and adherence than from broad primary-care prescribing.
What drives Sucraid revenue growth?
Revenue growth can come from:
- Increased awareness of CSID among gastroenterologists.
- Wider use of genetic, breath, or enzyme-function testing.
- More frequent diagnosis among patients previously classified as having irritable bowel syndrome.
- Improved insurer coverage.
- Higher persistence among treated patients.
- Expansion of specialist and specialty-pharmacy access.
- International commercialization or licensing.
The strongest long-term growth lever is diagnosis. Because sacrosidase is tied to a specific enzyme deficiency, the market cannot expand materially without identifying additional patients who have clinically meaningful sucrase deficiency.
What limits Sucraid revenue?
The main constraints are:
- Symptom overlap with more common gastrointestinal conditions.
- Limited awareness of CSID.
- Reimbursement friction for a rare-disease product.
- Dietary alternatives that some patients may use instead of medication.
- Dependence on QOL Medical’s commercial infrastructure.
- The absence of publicly verified pricing and utilization data.
- Potential pressure from compounded or alternative enzyme products, although these may not be therapeutically equivalent or FDA-approved substitutes.
When did Sucraid lose orphan-drug exclusivity?
Sucraid received FDA approval in 2001 and benefited from seven years of orphan-drug exclusivity. That period ended in 2008.
Orphan-drug exclusivity prevents FDA approval of the same drug for the same indication during the exclusivity term, subject to statutory exceptions. It does not prevent all forms of competition, and it does not create permanent market exclusivity. [2]
| Milestone |
Timing |
| FDA approval |
2001 |
| Seven-year orphan exclusivity |
Approximately 2001-2008 |
| Orphan exclusivity status today |
Expired |
| Current commercial protection |
Brand recognition, manufacturing know-how, distribution, reimbursement, and possible patent or regulatory rights |
Because the orphan exclusivity period has expired, a competing applicant could theoretically pursue approval for the same active ingredient and indication if it satisfied FDA requirements and resolved applicable patent or regulatory barriers.
What patents protect Sucraid?
The public FDA prescribing information identifies sacrosidase and the approved use but does not provide a complete commercial patent strategy for Sucraid. Patent protection must be evaluated through current USPTO records, FDA Orange Book data, assignment records, and litigation databases.
Sucraid’s commercial position is not dependent solely on the original orphan exclusivity period. Relevant protection categories include:
Formulation patents
Potential formulation protection would address the liquid enzyme composition, stabilizers, pH, storage conditions, enzyme activity, and container system. These protections can be important for an oral enzyme product because sacrosidase stability and activity may be sensitive to temperature, dilution, and formulation conditions.
Method-of-use patents
Method-of-use claims could cover the treatment of sucrase deficiency, CSID, carbohydrate intolerance, or specified patient populations. The practical value of such patents depends on listing status, claim scope, enforceability, and whether a generic or follow-on applicant can omit the protected indication.
Manufacturing patents and know-how
Manufacturing protection may cover recombinant production in yeast, fermentation conditions, purification, activity control, formulation, and quality testing. Even when patents expire, manufacturing know-how can remain a barrier because an entrant must consistently produce an active digestive enzyme with acceptable stability and batch-to-batch performance.
Orange Book status
Sucraid was approved under an NDA rather than a modern biosimilar BLA. A current Orange Book review is required to establish whether any unexpired patents are listed against the product and whether those listings are relevant to a Paragraph IV challenge. Patent status can change through delisting, expiration, pediatric extensions, terminal disclaimers, or litigation outcomes.
A public commercial conclusion should not treat orphan exclusivity as current patent protection. The two rights are legally distinct.
Are there Paragraph IV challenges to Sucraid?
No widely reported Paragraph IV litigation involving Sucraid has established a current generic-entry event in the public record through the latest broadly available information.
A generic applicant filing an ANDA with a Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. The NDA holder could then initiate patent litigation, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework. [3]
The risk is moderated by the product’s market size. A prospective entrant would need to justify:
- Development and bioequivalence costs.
- Enzyme activity and stability testing.
- Manufacturing scale-up.
- Specialty distribution.
- Payer contracting.
- A sufficiently large treated population.
For a low-volume rare-disease product, litigation and manufacturing costs may be difficult to support unless the incumbent’s net price is high or the entrant can secure a meaningful share of prescriptions.
Is Sucraid exposed to biosimilar competition?
Sucraid has potential exposure to biological-product competition, but no approved biosimilar or interchangeable sacrosidase product is widely identified in the U.S. market.
The FDA biosimilar pathway under section 351(k) could become relevant to a biological product with sufficient reference-product information and an approvable analytical and clinical development package. Sacrosidase is a recombinant enzyme, which creates technical comparability issues involving:
- Enzyme activity.
- Protein structure and glycosylation.
- Purity and aggregation.
- Stability after dilution.
- Immunogenicity.
- Functional performance in the gastrointestinal tract.
The commercial opportunity for a biosimilar is narrower than the opportunity for a high-volume monoclonal antibody. The product is administered orally, which may reduce some systemic immunogenicity concerns, but it does not eliminate the need to demonstrate consistent functional performance.
No biosimilar threat currently appears to have changed Sucraid’s U.S. market structure. The more immediate competition risk is a new sacrosidase product, an alternative enzyme product, or a clinically accepted non-drug dietary management strategy.
What is the FDA regulatory status of Sucraid?
Sucraid is FDA-approved for sucrase deficiency in patients with CSID. Its label is narrow and does not establish approval for all forms of chronic diarrhea, irritable bowel syndrome, or general carbohydrate intolerance.
FDA regulatory considerations include:
- The product’s prescription status.
- The approved CSID indication.
- Label-specific dosing by patient weight.
- Refrigerated storage requirements.
- Handling restrictions involving hot liquids.
- The need for manufacturing controls appropriate to a recombinant enzyme.
Because Sucraid is a chronic-use product, postmarketing attention is likely to focus on medication errors, storage and handling, allergic reactions, tolerability, and continued manufacturing quality.
Which companies compete with Sucraid?
QOL Medical is the principal U.S. commercial company associated with Sucraid. The competitive landscape is fragmented rather than populated by a direct branded rival.
| Competitor category |
Competitive threat |
| Direct sacrosidase product |
Highest potential threat, but no established U.S. competitor is broadly visible |
| Other digestive enzymes |
Limited substitution because composition and indication differ |
| Dietary sucrose restriction |
Practical alternative for some patients |
| Diagnostic substitutes |
Can affect prescribing by changing how patients are classified |
| Compounded enzyme products |
Possible price or access pressure, subject to quality and legal constraints |
| Emerging CSID therapies |
Long-term risk if a more convenient or less expensive product reaches approval |
Sucraid’s competitive advantage is its approved indication, accumulated physician experience, and established access model. Its weakness is that the product depends on a relatively narrow diagnosis and requires meal-linked administration.
What generic launch scenarios exist for Sucraid?
Three launch scenarios are commercially plausible.
Scenario 1: No direct entrant
QOL Medical retains the market because the treated population is small and technical development economics are unattractive. This is the most favorable scenario for continued brand revenue.
Scenario 2: Limited generic or follow-on entry
A competitor launches after resolving patent and regulatory barriers. The entrant captures price-sensitive patients, Medicaid volume, or selected payer accounts while QOL Medical retains patients who value continuity and established support services.
Scenario 3: Multiple entrants
Several companies pursue sacrosidase or related enzyme products. This would create pricing pressure, payer substitution, and lower brand persistence. The probability depends on the size of the diagnosed market, the net price, and the availability of enforceable patent claims.
A generic launch would not necessarily produce the steep erosion seen in large primary-care markets. Rare-disease products often retain meaningful share because physician control, patient support, supply reliability, and payer policy matter alongside price.
What licensing deals affect Sucraid?
No major publicly disclosed licensing transaction has established a new global commercialization structure for Sucraid in the broadly available public record. QOL Medical remains the central commercial entity associated with the product.
Any future licensing or acquisition would likely be assessed on:
- U.S. net sales and patient count.
- International rights.
- Manufacturing transferability.
- Patent and regulatory status.
- Payer restrictions.
- Diagnostic expansion potential.
- Dependence on a single product.
Because Sucraid is a focused rare-disease asset, a transaction would probably be valued on durable specialty revenue and strategic fit rather than blockbuster-scale volume.
How strong is the Sucraid patent estate?
Sucraid has a commercially durable position, but the strength of its current patent estate cannot be rated from orphan exclusivity alone. The strongest non-patent barriers are the specialized product profile, small patient base, manufacturing requirements, and established access infrastructure.
| Protection factor |
Current assessment |
| Orphan exclusivity |
Expired |
| Brand recognition |
Established in CSID |
| Direct competition |
Limited publicly visible competition |
| Manufacturing complexity |
Meaningful for recombinant enzyme production |
| Diagnosis barrier |
High |
| Payer barrier |
Material |
| Patent visibility |
Requires current Orange Book and USPTO verification |
| Biosimilar risk |
Theoretical, not an established current market threat |
| Generic risk |
Possible, but economics may limit entry |
The estate is commercially stronger than the expired orphan right suggests, but weaker than a product with active, broad, long-dated composition-of-matter protection.
Key Takeaways
- Sucraid is an FDA-approved sacrosidase oral solution for CSID.
- QOL Medical is the principal U.S. commercial company.
- The seven-year orphan-drug exclusivity period expired in approximately 2008.
- Public sources do not disclose audited Sucraid revenue, patient count, pricing, or profitability.
- The market is high value per patient but limited by diagnosis, reimbursement, and disease awareness.
- No widely reported approved generic or biosimilar has displaced Sucraid in the U.S. market.
- Manufacturing quality, enzyme stability, specialty distribution, and payer support are meaningful barriers to entry.
- Revenue growth depends more on diagnosis and treatment persistence than on broad population prescribing.
- Current patent exposure requires a live Orange Book, USPTO, and litigation review; orphan exclusivity should not be treated as continuing patent protection.
FAQs About Sucraid Market and Exclusivity
Is Sucraid a biologic drug?
Sucraid contains sacrosidase, a recombinant enzyme produced using yeast. It is a biological product in substance, although its original FDA approval was submitted under an NDA framework rather than the modern biosimilar BLA structure.
Does Sucraid have FDA orphan-drug exclusivity today?
No. The original seven-year orphan-drug exclusivity period associated with the 2001 approval expired approximately seven years later, in 2008.
Can a generic company launch sacrosidase?
A competitor could pursue an applicable FDA pathway, but it would need to address product equivalence, manufacturing, patent certifications, and the economics of a small specialty market.
Why is Sucraid expensive relative to ordinary digestive enzymes?
Sucraid is a prescription recombinant enzyme for a rare diagnosed disorder. Its cost structure reflects specialized manufacturing, quality controls, refrigerated distribution, patient-support services, and a limited treatment population.
What is the largest commercial risk to Sucraid?
The largest risk is a combination of diagnosis stagnation and future follow-on competition. If diagnosis does not expand, revenue growth remains constrained. If a technically comparable competitor enters, pricing and payer access could weaken.
References
-
U.S. Food and Drug Administration. (2023). Sucraid (sacrosidase) oral solution prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.